MedPath

Retrospective Study of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal Cancer Patients Receiving Oxaliplati

Not Applicable
Conditions
Colon cancer, gastric cancer, esophageal cancer, pancreatic cancer, biliary tract cancer, small intestine cancer, appendix cancer
Registration Number
JPRN-UMIN000052950
Lead Sponsor
St. Marianna Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
110
Inclusion Criteria

Not provided

Exclusion Criteria

Cases in which the principal investigator determines that participation in this study is inappropriate

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of chemotherapy-induced peripheral neuropathy of Grade 2 or higher with or without proton pump inhibitor or H2-receptor antagonist use
Secondary Outcome Measures
NameTimeMethod
Time to onset of grade 2 or higher chemotherapy-induced peripheral neuropathy with and without use of proton pump inhibitors and H2-receptor antagonists, and percentage of chemotherapy intolerance due to chemotherapy-induced peripheral neuropathy
© Copyright 2025. All Rights Reserved by MedPath